Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1637 1671 1681 1682
This examiner grants 38% of resolved cases
Francesca Filippa Giammona, in Tech Center 1600 and Art Unit 1637, has resolved 80 cases with an allowance rate of 37.5%. The median days to allowance is 1469, indicating a challenging and lengthy prosecution process. This 1469-day figure and the 37.5% allowance rate are the primary metrics for practitioners to consider. The 80 resolved cases provide a basis for understanding the examiner's typical requirements in this art unit.
However, the interview lift is 57.4%, which is exceptionally high compared to the 37.5% allowance rate. This 57.4% lift suggests that interviews are the most critical factor for success with this examiner. Practitioners should use interviews early to overcome the difficulties reflected in the 1469-day median pendency. The 57.4% lift provides a strong incentive for oral advocacy to improve the probability of success beyond the 37.5% baseline. These figures are essential for strategic planning.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17925693 | METHODS FOR DETECTION OF DONOR-DERIVED CELL-FREE DNA | Non-Final OA | Natera, Inc. |
| 17413464 | METHODS FOR ANALYSIS OF CIRCULATING CELLS | Non-Final OA | Natera, Inc. |
| 18294322 | COMPOSITIONS, KITS, AND METHODS FOR DETECTION OF NUCLEIC ACID SEQUENCE LOADS | Non-Final OA | Life Technologies Corporation |
| 18027087 | RANDOM INSERTION GENOME RECONSTRUCTION | Final Rejection | GOOGLE LLC |
| 19326091 | COMPOSITIONS AND METHODS OF MAKING GENE EXPRESSION LIBRARIES | Non-Final OA | 10x Genomics, Inc. |
| 17789131 | PRIMER SET AND METHOD FOR DETECTING TARGET NUCLEIC ACID USING SAME | Non-Final OA | KANEKA CORPORATION |
| 18629922 | Kaposi sarcoma associated herpesvirus gene function | Non-Final OA | The Regents of the University of California |
| 17926441 | COMPOSITIONS AND METHODS OF A NUCLEASE CHAIN REACTION FOR NUCLEIC ACID DETECTION | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18248121 | MASSIVELY SCALABLE VIRAL TESTING AND ASYMPTOMATIC SURVEILLANCE | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 17765620 | DIAGNOSIS AND TREATMENT OF THYROID CANCER | Non-Final OA | Beth Israel Deaconess Medical Center, Inc. |
| 17421677 | RAPID REVERSE TRANSCRIPTION QUANTITATIVE POLYMERASE CHAIN REACTION | Final Rejection | Northwestern University |
| 17580425 | COMPOSITIONS AND METHOD FOR DETECTING HUMAN PARVOVIRUS NUCLEIC ACID AND FOR DETECTING HEPATITIS A VIRUS NUCLEIC ACIDS IN SINGLE-PLEX OR MULTIPLEX ASSAYS | Final Rejection | GEN-PROBE INCORPORATED |
| 17441526 | Compositions and Methods for Detecting Group A Streptococcus | Non-Final OA | Gen-Probe Incorporated |
| 17382568 | DETECTION OF DRUG-RESISTANT MYCOPLASMA GENITALIUM | Non-Final OA | GEN-PROBE INCORPORATED |
| 18027561 | METHOD FOR PREDICTION OF RECURRENCE OR PROGNOSIS OF DIABETIC FOOT ULCER BY USING SPECIFIC METHYLATION OF GENE | Final Rejection | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION |
| 18248285 | METHODS AND MEANS FOR AMPLIFICATION-BASED QUANTIFICATION OF NUCLEIC ACIDS | Final Rejection | Imperial College Innovations Limited |
| 17905784 | NOVEL NUCLEIC ACID TEMPLATE STRUCTURE FOR SEQUENCING | Non-Final OA | Roche Sequencing Solutions, Inc. |
| 18190809 | SYSTEMS AND METHODS OF SEQUENCING POLYNUCLEOTIDES | Non-Final OA | Illumina, Inc. |
| 18000666 | SELECTING APTAMERS USING SEQUENCING | Non-Final OA | Illumina, Inc. |
| 18037222 | COMPOSITION FOR DETECTING TARGET NUCLEIC ACID AND METHOD FOR DETECTING TARGET NUCLEIC ACID USING SAME | Non-Final OA | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY |
| 17374691 | NUCLEASE-ASSOCIATED END SIGNATURE ANALYSIS FOR CELL-FREE NUCLEIC ACIDS | Final Rejection | GRAIL, Inc. |
| 18417800 | METHODS FOR ANALYSIS OF CELL-FREE NUCLEIC ACIDS IN URINE | Non-Final OA | GRAIL, LLC |
| 18066953 | COMPOSITIONS AND METHODS FOR DETECTION OF VARIANTS | Non-Final OA | Twist Bioscience Corporation |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy